Germline mutations in cancer-predisposition genes in patients with biliary tract cancer

Takeshi Terashima1,2, Kumiko Umemoto3, Hideaki Takahashi3, Hiroko Hosoi2, Erina Takai1, Shunsuke Kondo2, Yasunari Sakamoto2, Shuichi Mitsunaga3, Izumi Ohno3, Yusuke Hashimoto3, Mitsuhito Sasaki3, Masafumi Ikeda3, Kazuaki Shimada5, Shuichi Kaneko1, Shinichi Yachida4, Kokichi Sugano6,7, Takuji Okusaka2 and Chigusa Morizane2

1Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan
2Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan
3Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
4Department of Cancer Genome Informatics, Graduate School of Medicine, Osaka University, Osaka, Japan
5Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, Tokyo, Japan
6Oncogene Research Unit/Cancer Prevention Unit, Tochigi Cancer Center Research Institute, Tochigi, Japan
7Department of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan

Correspondence to: Chigusa Morizane, email: cmorizan@ncc.go.jp

Keywords: germline mutations; biliary tract cancer; hereditary breast cancer syndrome; hereditary ovarian cancer syndrome; cancer-predisposition genes

Received: July 22, 2019 Accepted: September 10, 2019 Published: October 15, 2019

ABSTRACT

The prevalence of germline mutations in patients with biliary tract carcinoma (BTC) remains unclear. Here, we investigated the prevalence and types of germline mutations in patients with BTC. We reviewed 269 patients with pathologically proven BTC and collected clinical characteristics, including medical and family histories. Additionally, we evaluated germline variants in 21 genes associated with hereditary predisposition for cancer by targeted sequencing in patients meeting ≥1 of the following criteria: 1) hereditary breast and/or ovarian cancer (HBOC) testing criteria modified for BTC, 2) Revised Bethesda Guidelines (RBGs) modified for BTC (modified RBG), 3) familial BTC criteria, or 4) young BTC criteria. Among the 269 patients, 80 met at least one criterion. Three pathogenic mutations in three patients were identified: two in BRCA2 and one in BRCA1. Among the 16 patients meeting modified HBOC testing criteria, 2 harbored germline BRCA2 mutations, and 1 harbored a germline BRCA1 mutation. However, no mutation in mismatch-repair genes were detected, despite 63 patients meeting modified RBG screening criteria and 18 qualifying as young BTC patients. We detected high prevalence of pathogenic germline mutations in BRCA1/2 and none in mismatch-repair genes in BTC patients following enrichment according to family or medical history in this study.

INTRODUCTION

The incidence of biliary tract carcinoma (BTC) is high in eastern Asia and continues to increase worldwide [1]. Patients with BTC have unsatisfactory outcomes, because the majority of them present with advanced and unresectable disease [2], with most patients subsequently developing recurrence, even after curative surgery [3].
Although combination chemotherapy with gemcitabine and cisplatin has become the standard care for patients with unresectable or recurrent BTC, its efficacy is limited, with an overall survival of <1 year [4, 5]. Therefore, BTC represents a major health concern. Several factors, including hepatolithiasis, parasitic infections, as typified by *Opisthorchis viverrini* which is unusual in Japan, primary sclerosing cholangitis, and specific toxins, have been identified as risk factors associated with BTC [6]; however, there are no reports regarding the frequency of germline mutations in cancer-predisposition genes in BTC.

Recently, knowledge concerning hereditary cancer syndrome has progressed, with sporadic studies reporting that BTC is caused by germline mutations in DNA mismatch-repair (MMR) genes, such as *MLH1*, *MSH2*, *MSH6*, and *PMS2*, capable of inducing Lynch syndrome [7]. Other germline mutations, such as *BRCA1* and *BRCA2*, which are known to be the respective causes of hereditary breast and/or ovarian cancer (HBOC) syndrome, were also identified in patients with BTC [8, 9]. Thus, a certain proportion of BTC must be caused by germline mutations in these cancer-predisposition genes; however, no systematic investigation concerning these hereditary cancer syndromes in BTC has been conducted, and their accurate prevalence remains unclear. Moreover, we hypothesized that young BTC patients would have characteristic genetic backgrounds [10]; however, information regarding this hypothesis is scarce. Here, we performed targeted sequencing of 21 representative genes related to hereditary cancer to investigate the prevalence of germline mutations in BTC patients.

**RESULTS**

**Patient characteristics**

Between May 2011 and March 2014, 269 patients were identified as having been pathologically diagnosed with BTC at the National Cancer Center Hospital and the National Cancer Center Hospital East. The patient characteristics are summarized in Table 1. The primary organs of the cancers included the intrahepatic bile duct (IHBD), extrahepatic bile duct (EHBD), gall bladder, and ampulla of Vater in 28.3%, 39.4%, 24.5%, and 7.8% of patients, respectively, which was consistent with a previous report [11]. Sixteen patients (5.9%), 63 patients (23.4%), 13 patients (4.8%), and 18 patients (6.7%) met the criteria for entry into the HBOC group, Lynch group, Familial BTC group, and Young BTC group, respectively. Because the germline DNA samples of six patients were unavailable, a total of 80 patients met at least one criterion and analyzed in this study (Figure 1).

**Analysis of germline variants**

Targeted sequencing showed that the patients harbored a median of 22 variants (range: 15–32) in the 21 targeted genes. Of these, three variants in three patients were considered pathogenic (Table 2), with the clinicopathologic characteristics of the patients shown in Table 1. Additionally, 57 variants in 50 patients were considered variants of unknown significance (VUS), with the clinicopathologic characteristics of these patients summarized in Supplementary Table 1.

The *BRCA1* variant c.3640G>T (p. Glu1214Ter) was detected in a male patient with EHBD cancer diagnosed at 65-years old. The patient had no history of malignant disease and had a family history of ovarian cancer diagnosed in a sister at 55-years old. The mutation was reportedly detected in the affected members from one family with ovarian cancer and a patient with breast cancer, but not in a healthy woman [12]. Another report described the mutation as detected in one family among 643 Dutch and 23 Belgian HBOC families [13]. Therefore, we classified the variants as pathogenic.

Two other *BRCA2* variants, c.5574_5577 delAATT (p. Ile1859Lys fsX3) and c.1887_1888 insA (p. Thr630Asn fsX6), resulting in frameshift mutations were detected in a male patient with IHBD cancer diagnosed at 57-years old and in a female patient with IHBD cancer diagnosed at 55-years old, respectively. They had no history of malignant disease; however, the former patient had a family history of metachronous cancers of the biliary tract and prostate cancer in the father and lung cancer in the mother, and the later patient had a family history of breast cancer diagnosed in an aunt at 30-years old. There were no studies reporting clinical significance or functional effects of the latter variant, whereas the former mutation was found in at least three families, two of which were kindred with more than three instances of breast cancer, suggesting it as the most frequent pathogenic variant in China [14]. Considering the effects of the former variant on the protein and interpretations as pathogenic according to dbSNP, we also classified this variant as pathogenic.

The prevalence and types of germline mutations classified as pathogenic according to the groupings used in this study are summarized in Figure 2. Three of 16 patients (18.8%), 20 of 63 patients (3.2%), 1 of 13 patients (7.7%), and none of 18 patients harbored pathogenic variants in the HBOC group, Lynch group, Familial BTC group, and Young BTC group, respectively. All 3 pathogenic variants detected in the HBOC group were *BRCA* genes whereas no mutation in mismatch-repair genes were detected despite 63 patients meeting modified RBG screening criteria. In regard to primary organs, 2 of 76 IHBD cancer patients (2.6%), 1 of 106 EHBD cancer patient (0.9%), and no gall bladder cancer and ampulla of Vater patients were found to have pathogenic variants.

www.oncotarget.com
Table 1: Patients characteristics

|                                | Overall (n = 269) | Analyzed patients in this study (n = 80) | HBOC group (n = 16) | Lynch group (n = 63) | Familial BTC group (n = 13) | Young BTC group (n = 18) |
|--------------------------------|-------------------|-----------------------------------------|---------------------|---------------------|-----------------------------|--------------------------|
| Age, years                     |                   |                                         |                     |                     |                             |                          |
| Median                         | 70                | 66                                      | 66                  | 67                  | 64                          | 48                       |
| Range                          | 26–90             | 26–90                                   | 51–78               | 26–90               | 45–73                       | 26–50                    |
| Gender, n (%)                  |                   |                                         |                     |                     |                             |                          |
| Male                           | 180 (66.9)        | 55 (68.8)                               | 11 (68.8)           | 41 (34.9)           | 11 (84.6)                   | 11 (61.1)                |
| Female                         | 89 (33.1)         | 25 (31.2)                               | 5 (31.3)            | 22 (65.1)           | 2 (15.4)                    | 7 (38.9)                 |
| Primary organ, n (%)           |                   |                                         |                     |                     |                             |                          |
| Intrahepatic bile duct        | 76 (28.3)         | 25 (31.3)                               | 3 (18.8)            | 22 (34.9)           | 4 (30.8)                    | 9 (50.0)                 |
| Extrahepatic bile duct        | 106 (39.4)        | 25 (31.3)                               | 7 (43.8)            | 17 (27.0)           | 6 (46.2)                    | 2 (11.1)                 |
| Gallbladder                    | 66 (24.5)         | 24 (30.0)                               | 5 (31.3)            | 19 (30.2)           | 2 (15.4)                    | 6 (33.3)                 |
| Ampulla of Vater              | 21 (7.8)          | 6 (7.5)                                 | 1 (6.3)             | 5 (7.9)             | 1 (7.7)                     | 1 (5.6)                  |
| Body mass index, Median        | 22.0              | 22.0                                    | 21.6                | 22.0                | 24.1                        | 23.6                     |
| Smoking Index, n (%)           |                   |                                         |                     |                     |                             |                          |
| <400                           | 159 (59.1)        | 35 (43.8)                               | 8 (50.0)            | 37 (58.7)           | 7 (53.8)                    | 14 (77.8)                |
| ≥400                           | 110 (40.9)        | 45 (56.3)                               | 8 (50.0)            | 26 (41.3)           | 6 (46.2)                    | 4 (22.2)                 |

Figure 1: Number of patients meeting criteria for inclusion in the HBOC group, Lynch group, Familial BTC group, and Young BTC group, respectively.
Table 2: Germline truncating mutation found in this study

| Patient ID | Gene     | Reference sequence | dbSNP Accession Number | Nucleotide change | Amino acid change | Type of mutation | dbSNP ClinVar PolyPhen2 MutationTaster FATHMM Our interpretation for pathogenicity |
|------------|----------|--------------------|------------------------|------------------|------------------|-----------------|---------------------------------------------------------------------------------|
| 19         | BRCA2    | NM_000059          | Rs397507568 c.10150 C>T| p. Arg3384Ter     | Nonsense         | VUS             | Conflicting                                              —           Disease causing — | VUS                                      |
| 31         | BRCA1    | NM_007294          | rs80356923 c.3640 G>T | p. Glu1214Ter     | Nonsense         | Other           | Pathogenic                                              —           Disease causing Cancer | Pathogenic                                |
| 37         | BRCA2    | NM_000059          | rs80359520 c.5574_5577 delAAATT | p. Ile1859Lys fs*3 | Frameshift       | Pathogenic      | Pathogenic                                              —           Disease causing — | Pathogenic                                |
| 57         | BRCA2    | NM_000059          | rs80359314 c.1887_1888 insA | p. Thr630Asn fs*6 | Frameshift       | Pathogenic      | Disease causing                                         —           Pathogenic                          |

Table 3: Clinicopathological characteristics of the patients with germline truncating mutation

| Patient ID | Gene | Previous cancer | Cancer in first- or second- degrees relatives | Age at onset, years | Sex | Primary organ of tumor * |
|------------|------|-----------------|-----------------------------------------------|---------------------|-----|-------------------------|
| 19         | BRCA2| None            | 1 breast, 1 lung, and 1 esophageal            | 65                  | M   | Gallbladder             |
| 31         | BRCA1| None            | 1 ovarian and 1 uterus                        | 65                  | M   | EHBD                    |
| 37         | BRCA2| None            | 1 prostate, 1 biliary, 1 uterus, and 1 colorectal | 57                  | M   | IHBD                    |
| 57         | BRCA2| None            | 1 breast                                      | 55                  | F   | IHBD                    |

* EHBD: extrahepatic bile duct, IHBD: intrahepatic bile duct.

Figure 2: The prevalence and types of germline mutations classified as pathogenic according to the groups used in this study.
DISCUSSION

Given the lack of studies investigating the frequency of germline mutations in cancer-predisposition genes associated with BTC, the importance of hereditary cancer syndromes in BTC remains unclear. Although insufficient attention has been given to the impact of family or medical history of cancers in relation to BTC-patient medical care, we hypothesized that proportions of BTC patients with a family history of cancer and/ or young-onset BTC patients would harbor germline mutations in cancer-predisposition genes, similar to colorectal cancer (CRC), ovarian cancer, and breast cancer. To select patients for genetic investigation, we referred to previously established testing criteria for HBOC, Lynch syndrome, and familial pancreatic cancer and modified them for suitability to BTC for this study. We subsequently performed targeted gene sequencing in patients with BTC to investigate the prevalence and types of germline mutations.

The most important insight gained from our results was that up to 19% of the patients enriched according to modified HBOC testing criteria harbored pathogenic variants in BRCA1/2. BRCA1/2 is involved in maintenance of genome stability, and inherited mutations in these genes increase lifetime risk of developing HBOC-related cancers [15, 16]. Germline mutations in BRCA1/2 or other HBOC-related genes are tested to determine whether the patients have a medical or family history of breast or/and ovarian cancer, with the prevalence of these mutations at >25% in patients with breast or ovarian cancer [17]. Here, BRCA1/2 variants were detected in a higher proportion of the patients than our expectation following adoption of the modified HBOC testing criteria.

We identified no MSH6, MLH1, MSH2, or PMS2 variants classified as pathogenic in BTC patients, despite enrichment according to modified RBGs focused on BTC instead of CRC. BTC is known to be one of Lynch syndrome-related tumors, and several clinical and case reports regarding Lynch syndrome-related BTC patients exist [7]. However, we could not find any patients in our study harboring germline mutation(s) of MMR genes contrary to our expectation. Recently universal tumor screening has been proposed for all colorectal and endometrial cancers [18, 19], and we cannot deny the usefulness of the widely accepted criteria as first-line screening criteria for Lynch syndrome; however, a previous study reported its exhibiting low specificity [20]; therefore, it might be necessary to establish other methods to enrich criteria associated with Lynch syndrome-related BTC patients. Similarly, specific genetic mutations were limited in the Familial and Young BTC groups among the 21 genes. In future work, whole-genome sequencing should be performed to investigate the genetic background of this cohort.

We did not determine the fourth BRCA2 variant found in this study, c.10150 C>T (p. Arg3384Ter), as pathogenic in consequence of sufficient for discussion because the variant located in the final exon and CIMBA criteria excluded the variants which truncate after codon 3326 which are currently considered neutral. However, the mutation was reported to detect among patients with unilateral breast cancer [21] and in a Korean patient with hereditary breast cancer [22]. This patient also had family histories of breast, lung, and esophagus. Considering this nonsense mutations causing truncation of the protein, additional studies will be needed to confirm our interpretation.

Increasing our understanding of the prevalence or types of germline mutations in patients with BTC benefits the development of improved screening methods for BTC or related cancers for patients and their families. Moreover, identification of these mutations offers more effective treatment possibilities for individual patients. Specific agents, such as platinum compounds or poly (ADP-ribose) polymerase (PARP) inhibitors, are effective treatments for some cancers involving BRCA1 or BRCA2 mutation [23–25]. Our results showing high prevalence of BRCA1 or BRCA2 variants in BTC patients also suggested BTC as a good target for the development of platinum or PARP-inhibitor therapeutics.

There were limitations to our study. First, we underestimated the impact of medical or family history of cancer due to the retrospective nature of the study. Second, we used a conservative approach to classifying the variants. At last, objective patients were restricted to Japanese. Therefore, further study is required to validate our findings.

In conclusion, up to 19% of the BTC patients in this study harbored pathogenic variants in BRCA1 and BRCA2 following patient classification according to modified HBOC testing criteria. No germline mutation in MMR genes was observed among following patient classification according to modified Revised Bethesda Guidelines in our study.

MATERIALS AND METHODS

Patients

Objective patients in this study were those with pathologically proven BTC, including cancers of the IHBD, EHBD, gall bladder, and ampulla of Vater, between May 2011 and March 2014 at the National Cancer Center Hospital (Tokyo, Japan) and the National Cancer Center Hospital East (Kashiwa, Japan). We reviewed the medical records of these patients and collected the following clinicopathologic features, as well as medical and family histories of any cancer in all relatives: age at onset, gender, body mass index, smoking history, and primary organ of tumor. The institutional Review Board at the National Cancer Center approved this study, which was conducted in accordance with the Declaration of Helsinki.
and Japanese national regulations, as well as the Ethical Guidelines for Medical and Health Research Involving Human Subjects (available: [https://www.mhlw.go.jp/file/06-Seisakujouhou-10600000-Daijinkanboukouseikagakuka/0000080278.pdf](https://www.mhlw.go.jp/)). Each patient provided informed consent.

### Criteria for targeted gene sequencing

Targeted gene sequencing was performed on samples from patients suspected of harboring any germline mutations based on their meeting one or more of the following criteria: 1) modified HBOC criteria which was based on BRCA1/2 testing criteria outlined by the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Genetic/Familial High-Risk Assessment version 2.2017 and modified by the addition of BTC as well as pancreatic and prostate cancer (HBOC group; Supplementary Table 2); 2) modified Revised Bethesda Guidelines (RBGs) which was based on RBGs for hereditary nonpolyposis CRC [26] modified by the addition of personal or family history within second-degree relatives of BTC to CRC (Lynch group; Supplementary Table 3); 3) familial BTC criteria; a patient with at least one first-degree relative with a history of BTC (Familial BTC group); and 4) young BTC criteria; a patient diagnosed with BTC at a young age (≤50-years old; Young BTC group).

### Massive parallel sequencing of target genes

Germline DNA samples were extracted from peripheral-blood leukocytes provided by the National Cancer Center Biobank, Japan. A custom targeted-capture kit was designed using NimbleDesign (NimbleGen, Madison, WI, USA) targeting the exons and splice-sites of 21 genes associated with hereditary predisposition for cancer (BRCA1, BRCA2, CHEK2, PALB2, ATM, BRIP1, TP53, PTEN, STK11, CDH1, NBN, BARD1, MLH1, MRE11, MSH2, MSH6, MUTYH, PMS1, PMS2, RAD50, and RAD51C). Sequencing libraries were created using the SeqCaq EZ Library (NimbleGen) and KAPA Library Preparation Kits (Kapa Biosystems, Wilmington, MA, USA) according to manufacturer protocol. Targeted-capture sequencing was performed on Illumina HiSeq2500 platforms (Illumina, San Diego, CA, USA). With the intent to maximize the sensitivity of variant detection, no variant-quality filters were applied. Bases were called using Illumina BCLFAST2 (Illumina). Paired-end reads were aligned to the human reference genome (GRCh37) using the Burrows-Wheeler Aligner [27]. A Genome Analysis Toolkit (GATK) was used to detect single-nucleotide substitutions and small insertions and deletions using best practices derived from the GATK website ([https://www.broadinstitute.org/gatk/](https://www.broadinstitute.org/gatk/)) [28].

### Variant characterization

Variants in 21 genes were considered for analysis if they met one of the following criteria: 1) a non-reference call by GATK; 2) predicted to affect the protein sequence or splice site (i.e., ±5 base pairs); and 3) a genotypic frequency of <1% in the 1,000 Genomes Project [29, 30], dbSNP [31], the Exome Aggregation Consortium ([https://www.broadinstitute.org/gatk/](https://www.broadinstitute.org/gatk/)), or the Japanese Human Genetic Variation Browser ([http://www.genome.med.kyoto-u.ac.jp/SnpDB/](http://www.genome.med.kyoto-u.ac.jp/SnpDB/)) and the Integrative Japanese Genome Variation Database ([https://ijgvd.megabank.tohoku.ac.jp/](https://ijgvd.megabank.tohoku.ac.jp/)). These rare, non-synonymous variants were classified as either pathogenic, benign, or VUS. Prediction by dbSNP or ClinVar ([https://www.ncbi.nlm.nih.gov/clinvar](https://www.ncbi.nlm.nih.gov/clinvar)) was used as a reference for our classification. For CDH1, MLH1, MSH2, MSH6, MUTYH, PMS1, and PMS2, variants were classified according to the InSiGHT consortium ([https://www.insight-group.org/variants/databases](https://www.insight-group.org/variants/databases)) [32]. For BRCA1 and BRCA2, variants were classified using the database generated by Valle et al. [33] and assessed using the Leiden Open Variation Database (LOVD) ([http://hci-exlovd.hci.utah.edu/home.php](http://hci-exlovd.hci.utah.edu/home.php)).

Rare, non-synonymous variants not found in these databases were classified based on their predicted effect on the protein product. Nonsense variants and variants changing the canonical splice sites (i.e., ±2 base pairs), as well as frameshift insertions and deletions, were considered pathogenic unless they occurred in the final exon. As for identification of functional missense mutations, SIFT ([http://sift.jcvi.org](http://sift.jcvi.org)) [34], Polyphen-2 ([http://genetics.bwh.harvard.edu/pph2/](http://genetics.bwh.harvard.edu/pph2/)) [35], MutationTaster ([http://www.mutationtaster.org](http://www.mutationtaster.org)) [36], and Functional Analysis through Hidden Markov Models ([http://fathmm.biocompute.org.uk](http://fathmm.biocompute.org.uk)) [37] were employed, as well as for a literature review. Classification of each VUS or pathogenic variant was determined by our medical genetics team, including two clinical geneticists in our hospital.

### Sanger sequencing

Variants classified as deleterious or likely deleterious in targeted-capture sequencing were validated by Sanger sequencing. Polymerase chain reaction (PCR) amplification was performed using 20 ng of genomic DNA with intronic primers flanking targeted exons. PCR products were sequenced using the M13F primer (5′-GTAAACGAGGCGCAG-3′) or the M13R primer (5′-CAGGAACACGTATGACC-3′) incorporated into the forward and reverse primers of each primer pair, respectively. These results were analyzed with Sequencher 5.0.1 software (Gene Codes, Ann Arbor, MI, USA).
Abbreviations

BTC: biliary tract carcinoma; HBC: hereditary breast and/or ovarian cancer; RBG: Revised Bethesda Guideline; MMR: mismatch-repair; IHBD: intrahepatic bile duct; EHBD: extrahepatic bile duct; VUS: variants of unknown significance; CRC: colorectal cancer; PARP: poly(ADP-ribose) polymerase; PCR: polymerase chain reaction.

Author contributions

T.T., E.T., S.Y., K.S., and C.M. designed the study, K.U., H.T., S.K., S.M., I.O., Y.H., M.S., M.I., K.S., T.O., and C.M. acquired the materials, T.T., H.H., E.T., S.Y., K.S. and C.M. analyzed and interpreted the data, T.T., H.T., E.T., S.Y., and C.M. wrote the draft of the manuscript, S.K., S.Y., K.S., and T.O. provided critical feedback, and all authors edited and reviewed the manuscript.

CONFLICTS OF INTEREST

The authors have no conflicts of interest to declare.

FUNDING

The National Cancer Center Research and Development Fund (25-A-1 and 28-A-1 to S.Y. and C.M., 28-A-3 to S.Y.). The National Cancer Center Biobank is supported by the National Cancer Center Research and Development Fund, Japan.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66:7–30. https://doi.org/10.3322/caac.21332. [PubMed]
2. Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer. 2016; 122:1349–1369. https://doi.org/10.1002/cncr.29692. [PubMed]
3. Furuse J, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, Kondo S, Saito H, Tsuyuguchi T, Hirakata K, Kimura F, Yoshitomi H, Nozawa S, et al. Guidelines for chemotherapy of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg. 2008; 15:55–62. https://doi.org/10.1002/jhp.197. [PubMed]
4. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362:1273–1281. https://doi.org/10.1056/NEJMoa0908721. [PubMed]
5. Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, Funakoshi A. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol. 2008; 62:849–855. https://doi.org/10.1007/s00280-007-0673-7. [PubMed]
6. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011; 54:173–184. https://doi.org/10.1002/hep.24351. [PubMed]
7. Mecklin JP, Jarvinen HJ, Virolainen M. The association between cholangiocarcinoma and hereditary nonpolyposis colorectal cancer. Cancer. 1992; 69:1112–1114. https://doi.org/10.1002/cncr.2820690508. [PubMed]
8. Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999; 91:1310–1316. https://doi.org/10.1093/jnci/91.15.1310. [PubMed]
9. Sharma MB, Carus A, Sunde L, Hamilton-Dutoit S, Ladekarl M. BRCA-associated pancreatico-biliary neoplasms: four cases illustrating the emerging clinical impact of genotyping. Acta Oncol. 2016; 55:377–381. https://doi.org/10.3322/10.1002/hep.24351. [PubMed]
10. Uhrhammer N, Abdelouahab A, Lafarge L, Feillel V, Ben Dilb A, Bignon YJ. BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases. Int J Med Sci. 2008; 5:197–202. https://doi.org/10.1002/jhm.197. [PubMed]
11. Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M, Hamamoto Y, Ishii H, Boku N, Furuse J. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 2013; 104:1211–1216. https://doi.org/10.1111/cas.12218. [PubMed]
12. Takano M, Aida H, Tsuneki I, Takakuwa K, Hasegawa I, Tanaka H, Saito M, Tsuji S, Sonoda T, Hatae M, Chen JT, Garcia-Closas M, Chatterjee BN, et al. Mutational analysis of BRCA1 gene in ovarian and breast-ovarian cancer families in Japan. Jpn J Cancer Res. 1997; 88:407–413. https://doi.org/10.1111/j.1349-7006.1997.tb0397x. [PubMed]
13. Peelen T, Van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C, van den Ouweland AM, Hogervorst F, Brohet R, Ligtenberg MJ, Teugels E, van der Luijt R, vander Hout AH, Gille JJ, et al. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet. 1997; 60:1041. [PubMed]
14. Pan M, Cong P, Wang Y, Lin C, Yuan Y, Dong J, Banerjee S, Zhang T, Chen Y, Zhang T, Chen M, Hu P, Zheng S, et al. Novel LOVD databases for hereditary breast cancer and colorectal cancer genes in the Chinese population. Hum Mutat. 2011; 32:1335–1340. https://doi.org/10.1002/humu.21588. [PubMed]
15. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med. 2003; 348:2339–2347. https://doi.org/10.1056/NEJMra012284. [PubMed]

16. Stratton MF, Gyller SA, Russell P, Dearden J, Gore M, Blake P, Easton D, Ponder BA. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med. 1997; 336:1125–1130. https://doi.org/10.1056/NEJM199704173361602. [PubMed]

17. Sugano K, Nakamura S, Ando J, Takayama S, Kamata H, Sekiguchi I, Ubukata M, Kodama T, Arai M, Kasumi F, Hirai Y, Ikeda T, Jinno H, et al. Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer. Cancer Sci. 2008; 99:1967–1976. https://doi.org/10.1111/j.1349-7006.2008.00944.x. [PubMed]

18. Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, Church JM, Dominitz JA, Johnson DA, Kaltenbach T, Levin TR, Lieberman DA, Robertson DJ, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology. 2014; 147:502–526. https://doi.org/10.1053/j.gastro.2014.04.001. [PubMed]

19. Vanse HF, Blanco I, Akhtan-Collan K, Goplie JP, Alonso R, Gao Y, Guo J, Vidal H, et al. Analysis of germline BRCA1 and BRCA2 mutations and variants of unknown clinical significance in a Spanish population: recent update of the Spanish Gastroenterological Association. Gastro. 2014; 147:502–526. https://doi.org/10.1053/j.gastro.2014.04.001. [PubMed]

20. Piñfol V, Castells A, Andreu M, Castells-Bel S, Alenda C, Llor X, Nicola RM, Rodriguez-Moranta F, Paya A, Jover R, Bessa X. Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Accuracy of Revised Bethesda Guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005; 293:1986–1994. https://doi.org/10.1001/jama.293.16.1986. [PubMed]

21. Borg A, Haile RW, Malone KE, Capanu M, Diep A, Törngren T, Teraoka S, Begg CB, Thomas DC, Concannon P, Mellemkjaer L, Barmstein L, Tellhed L, et al. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WE-CARE Study. Hum Mutat. 2010; 31:E1200–E1240. https://doi.org/10.1002/humu.21202. [PubMed]

22. Kang E, Seong MW, Park SK, Lee JW, Lee J, Kim LS, Lee JE, Kim SY, Jeong J, Han SA, Kim SW; Korean Hereditary Breast Cancer Study Group. The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study. Breast Cancer Res Treat. 2015; 151:157–168. https://doi.org/10.1007/s10549-015-3377-4. [PubMed]

23. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015; 33:244–250. https://doi.org/10.1200/JCO.2014.56.2728. [PubMed]

24. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomized phase 2 trial. Lancet Oncol. 2014; 15:852–861. https://doi.org/10.1016/S1470-2045(14)70228-1. [PubMed]

25. Muggia F, Safra T. ‘BRCAness’ and its implications for platinum action in gynecologic cancer. Anticancer Res. 2014; 34:551–556. [PubMed]

26. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004; 96:261–268. https://doi.org/10.1093/jnci/djh034. [PubMed]

27. Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics. 2009; 25:1754–1760. https://doi.org/10.1093/bioinformatics/btp324. [PubMed]

28. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20:1297–1303. https://doi.org/10.1101/gr.107524.110. [PubMed]

29. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, Hurles ME, McVean GA; 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature. 2010; 467:1061–1068. https://doi.org/10.1038/nature09534. [PubMed]. Erratum in: Nature. 2011 May 26;473(7348):544. Xue, Yali Q, et al. [PubMed]

30. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA; 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 491:56–65. https://doi.org/10.1038/nature11632. [PubMed]

31. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirokin K. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001; 29:308–311. https://doi.org/10.1093/nar/29.1.308. [PubMed]
32. Thompson BA, Spurle AB, Plazzer JP, Greenblatt MS, Akagi K, Al-Mulla F, Bapat B, Bernstein I, Capella G, den Dunnen JT, du Sart D, Fabre A, Farrell MP, et al. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet. 2014; 46:107–115. https://doi.org/10.1038/ng.2854. [PubMed]

33. Vallee MP, Francy TC, Judkins MK, Babikyan D, Lesueur F, Gammon A, Goldgar DE, Couch FJ, Tavitigian SV. Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs. Hum Mutat. 2012; 33:22–28. https://doi.org/10.1002/humu.21629. [PubMed]

34. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009; 4:1073–1081. https://doi.org/10.1038/nprot.2009.86. [PubMed]

35. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods. 2010; 7:248–249. https://doi.org/10.1038/nmeth0410-248. [PubMed]

36. Schwarz JM, Cooper DN, Schuelke M, Seelow D. Mutation Taster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014; 11:361–362. https://doi.org/10.1038/nmeth.2890. [PubMed]

37. Shihab HA, Gough J, Cooper DN, Day IN, Gaunt TR. Predicting the functional consequences of cancer-associated amino acid substitutions. Bioinformatics. 2013; 29:1504–1510. https://doi.org/10.1093/bioinformatics/btt182. [PubMed]